Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE4
Total Enrollment
660 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-12-29
Study Completion Date
2027-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Introduction:
Lactoferrin has several uses due to its effects. It has anti-inflammatory, antioxidant, immunomodulatory, antibacterial, antifungal, and antiviral effects. Its safety is proven by food and drug administration.
Aims:
The objective is to study the effect of lactoferrin on improving clinical outcomes in ICU patients, and also to evaluate its safety.
Patients and populations:
A sample of 660 patients (330 patients in both groups A, and B) who will be admitted to ICU departments in Mansoura university hospital will be used to represent the population in ICU.
Methods:
A sample of 660 participants was randomized 1:1 into two groups (group A (330 patients), and group B (330 patients)).
This study is a single blind, randomized controlled clinical trial. Randomization was performed by independent clinical pharmacists working in hospital ICU departments.
Lactoferrin has several uses due to its effects. It has anti-inflammatory, antioxidant, immunomodulatory, antibacterial, antifungal, and antiviral effects. Its safety is proven by food and drug administration.
Aims:
The objective is to study the effect of lactoferrin on improving clinical outcomes in ICU patients, and also to evaluate its safety.
Patients and populations:
A sample of 660 patients (330 patients in both groups A, and B) who will be admitted to ICU departments in Mansoura university hospital will be used to represent the population in ICU.
Methods:
A sample of 660 participants was randomized 1:1 into two groups (group A (330 patients), and group B (330 patients)).
This study is a single blind, randomized controlled clinical trial. Randomization was performed by independent clinical pharmacists working in hospital ICU departments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Complementary Intervention for COVID-19
NCT04487964
COVID-19
COMPLETED
NA
Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19
NCT04961476
Covid19
Fatigue Syndrome, Chronic
COMPLETED
Beta-alanine Supplementation and CrossFit Performance
NCT05772988
Exercise-Induced Lactic Acidemia
COMPLETED
NA
Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients
NCT05765617
COVID-19
COMPLETED
PHASE2
Role of Mega Dose of Vitamin C in Critical COVID-19 Patients
NCT04682574
Corona Virus Infection
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Introduction
1.1. Lactoferrin molecule
Lactoferrin (LF) is iron linking milk protein. LF helps to modulate iron levels in the body \[1-3\]. LF is a part of the milk whey protein. The colostrum (the first milk produced by mothers after delivery) has seven times more LF than mature milk \[4\]. LF is found in many organs like kidneys, lungs, gallbladder, pancreas, intestine, liver, prostate, and also in the body fluids like saliva, tears, sperm, cerebrospinal fluid, urine, bronchial secretions, vaginal discharge, synovial fluid, umbilical cord blood, blood plasma, and immune cells \[1,2,4\]. LF has many beneficial effects in the body. It has antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effects \[5\]. Figure 1: different effects of lactoferrin \[5\]
1.2. Lactoferrin as antioxidant molecule
The body is affected by several factors such as pathogens, environmental pollutants, and toxins. This leads to the development and accumulation of reactive oxygen species (ROS) in the body which is known as oxidative stress. ROS can cause many diseases. LF can stop the harm induced by ROS \[6, 7\], and enhance the activity of endogenous antioxidant pathways \[8\].
LF acts as a neuroprotective agent in Parkinson's disease and Alzheimer's disease \[9\]. It also protects against osteoporosis by inhibition of osteoblast activity and due to its antioxidant effect \[10\]. LF improves glucose metabolism in patients with type 2 diabetes mellitus via enhancement of the insulin-mediating response \[11\] and prevents obesity due to imbalance in body fat metabolism \[12\]. It also reduces blood pressure in hypertension \[13\]. So, LF can act as anti-hyperglycemic, and anti-hypertensive agent.
1.3. Lactoferrin as antipathogenic and immunomodulating molecule LF has antibacterial activity against Gram-positive and Gram-negative bacteria, as it kills pathogens, and prevents the biofilm formation by Staphylococcus aureus or Pseudomonas aeruginosa \[14\]. LF also prevents viral, bacterial, fungal and protozoal gastrointestinal tract infections \[15\]. It enhances the treatment of Helicobacter pylori gastric infection \[16\], and also protects against endotoxemia, bacteremia, sepsis and necrotic enteritis after partial bowel resection \[17\] and in neonates \[18\]. LF possess an antiviral activity and enhances the effect of antiviral drugs \[19\].
It acts as antiviral agent by blocking the pathogen's surface receptors and prevents it from binding to the target cell, for example, its binding to angiotensin converting enzyme II receptors which used by SARS-CoV-2 to pass cell membrane and thus inhibit virus entry into the cell \[20\].
LF also has antifungal effect against dermatophytes and enhance the effect of antifungal drugs \[21\]. In addition, it has an antiparasitic effect in treatment of toxoplasmosis and malaria \[22\].
It also has an immunomodulating effect, stimulating the body to synthesize cytokines and chemokines as well as accelerating the maturation of the immune system cells \[3, 23\].
LF possesses also anti-inflammatory activity in non-infectious disorders such as allergies, arthritis, cancer \[24\] and inflammatory colitis \[25\]. Its anti-inflammatory effect is due to the inhibition of ROS to prevent lipid peroxidation by chelating iron. It also enhances the production of anti-inflammatory cytokines (IL-10) and suppresses the production of pro-inflammatory cytokines (IL-6, IL-8, IL-1b, and TNF-α). In addition, It can enter into mast cells and interact with the inflammatory proteases (chymase, cathepsin G, and tryptase) \[26\].
1.5. Lactoferrin for anemia of inflammation
LF treats inflammatory disorders by increasing ferroprotein production and decreasing IL-6 level to redistribute endogenous iron between blood and tissue. So, LF is used as therapy for anemia caused by inflammation \[27\].
1.6. Safety of lactoferrin use
The safety of LF is proved by the Food and Drug Administration. However, bovine LF, as an ingredient in cow's milk, may cause hypersensitivity, So, lactoferrin use has a risk of allergic reaction, and contraindicated in case of hypersensitivity to cow's milk proteins, and in lactose intolerance \[28\]. Other side effects of LF include stomach pain, vomiting, and constipation \[29\].
2. Aim of the study
The objective is to study the effect of lactoferrin on improving clinical outcomes in ICU patients, and also to evaluate its safety.
3. Methods
3.1. Study design
The research will be a single-blind, randomized, controlled clinical trial to evaluate the efficacy and safety of a drug. Randomization will be 1:1 and achieved by independent clinical pharmacists who are working in ICU departments of the hospital. The patients will be blinded for identification of treatment, and placebo groups. Allocation of patients into their groups will be made after checking for meeting inclusion and not meeting exclusion criteria within 24 hours of the admission to ICU. All patients will receive the standard of care at admission.
3.2. Patients and populations
A total of 660 patients who will be admitted to ICU departments in Mansoura University Hospital will represent the population in ICU.
3.3. Intervention
One group will receive a two sachet of 100 mg lactoferrin enterally (either orally or by Ryle tube) every 12 hours (400 mg daily) for 28 days plus the standard of care. another group will receive the standard of care only.
A sample of 660 patients (330 patients in both 2 groups (group A: lactoferrin and group B: standard group) who will be admitted to ICU departments in Mansoura university hospital will be used to represent the population in ICU. The standard group (B) will be divided into three subgroups of 110 patients in each. Subgroup B1 will receive standard antioxidant drug (Acetyl cysteine 600 mg / 12 hr) orally to be compared with lactoferrin A1 subgroup.
\- Subgroup B2 will receive standard anti-inflammatory, and immunomodulatory drug (dexamethasone I.V 8 mg / day) to be compared with lactoferrin A2 subgroup.
* Subgroup B3 will receive standard antibacterial drugs to be compared with lactoferrin A3 subgroup.
3.4. Outcomes and parameters
Primary outcomes:
* 28-day mortality (efficacy), and
* incidence of any allergic or hypersensitivity reactions (safety).
Secondary outcomes:
• the day of death,
• need for invasive mechanical ventilation (IMV),
• duration of need for oxygen therapy, and IMV,
• duration of ICU stay, and
• kidneys, and liver functions.
• Glasgow coma score (GCS) and
• sequential organ function assessment (SOFA) score \[31\].
• The changes in biochemical markers
Blood sample collection:
About 5 ml venous blood samples will be withdrawn by sterile venipuncture and centrifugated at 3000 rpm for 15 min, then sera will be kept frozen at 8 oC until analysis of • CBC • Inflammatory marker (TNF-α) • Oxidant marker (TAC)
* Liver functions
* Kidney functions In addition, arterial blood gases (ABG), vital signs, and Oxygen saturation were measured.Most of these parameters are measured in previous researches \[32-39\]
Subgroup analysis will be conducted in order to compare lactoferrin with other drugs with relevant activity as shown below:
1- A comparison between the adjuvant antibacterial effect of lactoferrin vs standard antibacterial drugs as indicated by the WBCs and its differential counts (neutrophils, macrophages) in case of bacterial infections.
2- A comparison between the antioxidant effect of lactoferrin vs standard antioxidant drug (Acetyl cysteine) indicated by Anti-oxidant marker (TAC) 3- A comparison between the anti-inflammatory effect of lactoferrin vs standard anti-inflammatory, and immunomodulatory drug (dexamethasone) as indicated by the inflammatory marker (TNF- α)
3.5 Statistical analysis and sample size
Statistical analysis:
Per-protocol strategy will be used in this study. Categorical variables will be presented as proportion and percent. Continuous variables will be presented as mean (standard deviation) if normally distributed or as a median (IQR) or (25th-75th percentile) for non-normally distributed data Mann-Whitney test, t-test or Chi-square test will be used to compare baseline characteristics and outcomes between the two groups. In comparison between the two groups, Chi-square test will be used to compare proportions for non-parametric data (nominal or categorical). Mann-Whitney test will be used to compare medians for non- normally distributed continuous parametric data. While t-test will be used only to compare means in case normally distributed continuous parametric. So, distributions of continuous data will be tested in order to know the correct test to be used in comparison of parametric data between the two groups. ANOVA test will be used in case of comparison between more than 2 groups (as in case of comparison of antioxidant therapies).
Investigators will report the 95% confidence interval and the P-value for our statistical tests with level of statistical significance will be p-value \< 0.05.
Regression analysis will be performed, if there is a statistically significant differences between the baseline characteristics including age, gender, No. of comorbidities (DM, hypertension (HTN), ischemic heart disease (IHD), atrial fibrillation (AF), COPD) in order to exclude the effect of these confounding variables on the study outcomes Investigators will compare the 28-day all-cause mortality rate, incidence of hypersensitivity reactions, and need for invasive mechanical ventilation (IMV) using the Chi-square test. while t-test will be used to compare the day of death, duration of need for oxygen therapy and IMV, and duration of ICU stay, and all parameter measured in the study if they will be normally distributed, but if they will be non-normally distributed, Mann-Whitney test will be used instead.
. Statistical analysis will be achieved with SPSS software, version 26.
Sample size:
The power of trial will depend on the primary outcome (28-day mortality). The proportion of ICU Population to all hospital population is about 25% A total sample sizes of 634 patients would achieve at least 80 % (0.8) power to detect a risk difference of 0.2 (20%) in the 28-day all-cause mortality (primary outcome) between alternative hypothesis and the null hypothesis (proportions of two groups are 0.5) with a significance level (α) of 0.05 and 95% confidence level proportion in Clincalc.com calculator \[62\]. To compensate for the estimated loss-to-follow-up and increase the study power more than 80%, Investigators will increase the sample size in both groups to be 660 patients (330 in each study group).
The mortality data will be estimated from the average mortality in January, February, and March 2025 at the Mansoura University Hospital ICU departments among all hospitalized patients. Mortality rate is found to be about 720 cases in these 3 months (240 cases / month) in ICU patients receiving the standard of care. The online system has been used to obtain mortality rate in these three months \[32-39\]. The hypothesis is that LF will decrease mortality by 20% so mortality rate will be decreased from 240 to 192 per month.
4\. Data Quality and Safety
Investigators will collect the data from hospital system directly into an excel sheet, Patient confidentiality will be kept before, during and after the study. Patients who will be discharged before 28 days of hospital stay, will be communicated at day 28 in order to know mortality at day 28.
5\. Publishing the study results and funding
Due to size limitations in publishing the research as one paper in a journal. Investigators aim to divide this research into five papers and publish these papers in peer-reviewed journals (5 stage publications).
Funding There is no funding source for this study
Conflict of interest The investigators declare no relevant conflict of interest
6\. Ethical Considerations
Ethical approval will be taken from
1. Institutional research board (IRB), faculty of medicine, Mansoura University,
2. Research ethics committee, faculty of pharmacy, Tanta University,
* Benefits of the intervention to the patients outweigh expected risks. Informed consents will be obtained from all participants in this research. Privacy of participants and the confidentiality of data will be maintained. Any unexpected risks that appeared during the research will be cleared to participants, the IRB, and ethical committees on time. All study procedures will obey the standard of the Declaration of Helsinki (1964) principles
1.1. Lactoferrin molecule
Lactoferrin (LF) is iron linking milk protein. LF helps to modulate iron levels in the body \[1-3\]. LF is a part of the milk whey protein. The colostrum (the first milk produced by mothers after delivery) has seven times more LF than mature milk \[4\]. LF is found in many organs like kidneys, lungs, gallbladder, pancreas, intestine, liver, prostate, and also in the body fluids like saliva, tears, sperm, cerebrospinal fluid, urine, bronchial secretions, vaginal discharge, synovial fluid, umbilical cord blood, blood plasma, and immune cells \[1,2,4\]. LF has many beneficial effects in the body. It has antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effects \[5\]. Figure 1: different effects of lactoferrin \[5\]
1.2. Lactoferrin as antioxidant molecule
The body is affected by several factors such as pathogens, environmental pollutants, and toxins. This leads to the development and accumulation of reactive oxygen species (ROS) in the body which is known as oxidative stress. ROS can cause many diseases. LF can stop the harm induced by ROS \[6, 7\], and enhance the activity of endogenous antioxidant pathways \[8\].
LF acts as a neuroprotective agent in Parkinson's disease and Alzheimer's disease \[9\]. It also protects against osteoporosis by inhibition of osteoblast activity and due to its antioxidant effect \[10\]. LF improves glucose metabolism in patients with type 2 diabetes mellitus via enhancement of the insulin-mediating response \[11\] and prevents obesity due to imbalance in body fat metabolism \[12\]. It also reduces blood pressure in hypertension \[13\]. So, LF can act as anti-hyperglycemic, and anti-hypertensive agent.
1.3. Lactoferrin as antipathogenic and immunomodulating molecule LF has antibacterial activity against Gram-positive and Gram-negative bacteria, as it kills pathogens, and prevents the biofilm formation by Staphylococcus aureus or Pseudomonas aeruginosa \[14\]. LF also prevents viral, bacterial, fungal and protozoal gastrointestinal tract infections \[15\]. It enhances the treatment of Helicobacter pylori gastric infection \[16\], and also protects against endotoxemia, bacteremia, sepsis and necrotic enteritis after partial bowel resection \[17\] and in neonates \[18\]. LF possess an antiviral activity and enhances the effect of antiviral drugs \[19\].
It acts as antiviral agent by blocking the pathogen's surface receptors and prevents it from binding to the target cell, for example, its binding to angiotensin converting enzyme II receptors which used by SARS-CoV-2 to pass cell membrane and thus inhibit virus entry into the cell \[20\].
LF also has antifungal effect against dermatophytes and enhance the effect of antifungal drugs \[21\]. In addition, it has an antiparasitic effect in treatment of toxoplasmosis and malaria \[22\].
It also has an immunomodulating effect, stimulating the body to synthesize cytokines and chemokines as well as accelerating the maturation of the immune system cells \[3, 23\].
LF possesses also anti-inflammatory activity in non-infectious disorders such as allergies, arthritis, cancer \[24\] and inflammatory colitis \[25\]. Its anti-inflammatory effect is due to the inhibition of ROS to prevent lipid peroxidation by chelating iron. It also enhances the production of anti-inflammatory cytokines (IL-10) and suppresses the production of pro-inflammatory cytokines (IL-6, IL-8, IL-1b, and TNF-α). In addition, It can enter into mast cells and interact with the inflammatory proteases (chymase, cathepsin G, and tryptase) \[26\].
1.5. Lactoferrin for anemia of inflammation
LF treats inflammatory disorders by increasing ferroprotein production and decreasing IL-6 level to redistribute endogenous iron between blood and tissue. So, LF is used as therapy for anemia caused by inflammation \[27\].
1.6. Safety of lactoferrin use
The safety of LF is proved by the Food and Drug Administration. However, bovine LF, as an ingredient in cow's milk, may cause hypersensitivity, So, lactoferrin use has a risk of allergic reaction, and contraindicated in case of hypersensitivity to cow's milk proteins, and in lactose intolerance \[28\]. Other side effects of LF include stomach pain, vomiting, and constipation \[29\].
2. Aim of the study
The objective is to study the effect of lactoferrin on improving clinical outcomes in ICU patients, and also to evaluate its safety.
3. Methods
3.1. Study design
The research will be a single-blind, randomized, controlled clinical trial to evaluate the efficacy and safety of a drug. Randomization will be 1:1 and achieved by independent clinical pharmacists who are working in ICU departments of the hospital. The patients will be blinded for identification of treatment, and placebo groups. Allocation of patients into their groups will be made after checking for meeting inclusion and not meeting exclusion criteria within 24 hours of the admission to ICU. All patients will receive the standard of care at admission.
3.2. Patients and populations
A total of 660 patients who will be admitted to ICU departments in Mansoura University Hospital will represent the population in ICU.
3.3. Intervention
One group will receive a two sachet of 100 mg lactoferrin enterally (either orally or by Ryle tube) every 12 hours (400 mg daily) for 28 days plus the standard of care. another group will receive the standard of care only.
A sample of 660 patients (330 patients in both 2 groups (group A: lactoferrin and group B: standard group) who will be admitted to ICU departments in Mansoura university hospital will be used to represent the population in ICU. The standard group (B) will be divided into three subgroups of 110 patients in each. Subgroup B1 will receive standard antioxidant drug (Acetyl cysteine 600 mg / 12 hr) orally to be compared with lactoferrin A1 subgroup.
\- Subgroup B2 will receive standard anti-inflammatory, and immunomodulatory drug (dexamethasone I.V 8 mg / day) to be compared with lactoferrin A2 subgroup.
* Subgroup B3 will receive standard antibacterial drugs to be compared with lactoferrin A3 subgroup.
3.4. Outcomes and parameters
Primary outcomes:
* 28-day mortality (efficacy), and
* incidence of any allergic or hypersensitivity reactions (safety).
Secondary outcomes:
• the day of death,
• need for invasive mechanical ventilation (IMV),
• duration of need for oxygen therapy, and IMV,
• duration of ICU stay, and
• kidneys, and liver functions.
• Glasgow coma score (GCS) and
• sequential organ function assessment (SOFA) score \[31\].
• The changes in biochemical markers
Blood sample collection:
About 5 ml venous blood samples will be withdrawn by sterile venipuncture and centrifugated at 3000 rpm for 15 min, then sera will be kept frozen at 8 oC until analysis of • CBC • Inflammatory marker (TNF-α) • Oxidant marker (TAC)
* Liver functions
* Kidney functions In addition, arterial blood gases (ABG), vital signs, and Oxygen saturation were measured.Most of these parameters are measured in previous researches \[32-39\]
Subgroup analysis will be conducted in order to compare lactoferrin with other drugs with relevant activity as shown below:
1- A comparison between the adjuvant antibacterial effect of lactoferrin vs standard antibacterial drugs as indicated by the WBCs and its differential counts (neutrophils, macrophages) in case of bacterial infections.
2- A comparison between the antioxidant effect of lactoferrin vs standard antioxidant drug (Acetyl cysteine) indicated by Anti-oxidant marker (TAC) 3- A comparison between the anti-inflammatory effect of lactoferrin vs standard anti-inflammatory, and immunomodulatory drug (dexamethasone) as indicated by the inflammatory marker (TNF- α)
3.5 Statistical analysis and sample size
Statistical analysis:
Per-protocol strategy will be used in this study. Categorical variables will be presented as proportion and percent. Continuous variables will be presented as mean (standard deviation) if normally distributed or as a median (IQR) or (25th-75th percentile) for non-normally distributed data Mann-Whitney test, t-test or Chi-square test will be used to compare baseline characteristics and outcomes between the two groups. In comparison between the two groups, Chi-square test will be used to compare proportions for non-parametric data (nominal or categorical). Mann-Whitney test will be used to compare medians for non- normally distributed continuous parametric data. While t-test will be used only to compare means in case normally distributed continuous parametric. So, distributions of continuous data will be tested in order to know the correct test to be used in comparison of parametric data between the two groups. ANOVA test will be used in case of comparison between more than 2 groups (as in case of comparison of antioxidant therapies).
Investigators will report the 95% confidence interval and the P-value for our statistical tests with level of statistical significance will be p-value \< 0.05.
Regression analysis will be performed, if there is a statistically significant differences between the baseline characteristics including age, gender, No. of comorbidities (DM, hypertension (HTN), ischemic heart disease (IHD), atrial fibrillation (AF), COPD) in order to exclude the effect of these confounding variables on the study outcomes Investigators will compare the 28-day all-cause mortality rate, incidence of hypersensitivity reactions, and need for invasive mechanical ventilation (IMV) using the Chi-square test. while t-test will be used to compare the day of death, duration of need for oxygen therapy and IMV, and duration of ICU stay, and all parameter measured in the study if they will be normally distributed, but if they will be non-normally distributed, Mann-Whitney test will be used instead.
. Statistical analysis will be achieved with SPSS software, version 26.
Sample size:
The power of trial will depend on the primary outcome (28-day mortality). The proportion of ICU Population to all hospital population is about 25% A total sample sizes of 634 patients would achieve at least 80 % (0.8) power to detect a risk difference of 0.2 (20%) in the 28-day all-cause mortality (primary outcome) between alternative hypothesis and the null hypothesis (proportions of two groups are 0.5) with a significance level (α) of 0.05 and 95% confidence level proportion in Clincalc.com calculator \[62\]. To compensate for the estimated loss-to-follow-up and increase the study power more than 80%, Investigators will increase the sample size in both groups to be 660 patients (330 in each study group).
The mortality data will be estimated from the average mortality in January, February, and March 2025 at the Mansoura University Hospital ICU departments among all hospitalized patients. Mortality rate is found to be about 720 cases in these 3 months (240 cases / month) in ICU patients receiving the standard of care. The online system has been used to obtain mortality rate in these three months \[32-39\]. The hypothesis is that LF will decrease mortality by 20% so mortality rate will be decreased from 240 to 192 per month.
4\. Data Quality and Safety
Investigators will collect the data from hospital system directly into an excel sheet, Patient confidentiality will be kept before, during and after the study. Patients who will be discharged before 28 days of hospital stay, will be communicated at day 28 in order to know mortality at day 28.
5\. Publishing the study results and funding
Due to size limitations in publishing the research as one paper in a journal. Investigators aim to divide this research into five papers and publish these papers in peer-reviewed journals (5 stage publications).
Funding There is no funding source for this study
Conflict of interest The investigators declare no relevant conflict of interest
6\. Ethical Considerations
Ethical approval will be taken from
1. Institutional research board (IRB), faculty of medicine, Mansoura University,
2. Research ethics committee, faculty of pharmacy, Tanta University,
* Benefits of the intervention to the patients outweigh expected risks. Informed consents will be obtained from all participants in this research. Privacy of participants and the confidentiality of data will be maintained. Any unexpected risks that appeared during the research will be cleared to participants, the IRB, and ethical committees on time. All study procedures will obey the standard of the Declaration of Helsinki (1964) principles
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Critical Illness
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lactoferrin
Lactoferrin 100 mg sachets with a dose of 200 mg (2 sachets) orally twice daily (400 mg per day) In addition to standard of care
Group Type
EXPERIMENTAL
Lactoferrin
Intervention Type
DRUG
antioxidant, immunomodulatory, anti-inflammatory, antimicrobial effect
Standard
Subgroup B1 will receive standard antioxidant drug (Acetyl cysteine 600 mg / 12 hr) orally to be compared with lactoferrin A1 subgroup.
* Subgroup B2 will receive standard anti-inflammatory, and immunomodulatory drug (dexamethasone I.V 8 mg / day) to be compared with lactoferrin A2 subgroup.
* Subgroup B3 will receive standard antibacterial drugs to be compared with lactoferrin A3 subgroup.
Group Type
ACTIVE_COMPARATOR
Antioxidant therapies
Intervention Type
DRUG
Acetyl cysteine 600 mg / 12 hr
Dexamethasone
Intervention Type
DRUG
dexamethasone I.V 8 mg / day
Antibacterial therapies
Intervention Type
DRUG
Antibacterial drugs in their approved doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactoferrin
antioxidant, immunomodulatory, anti-inflammatory, antimicrobial effect
Intervention Type
DRUG
Antioxidant therapies
Acetyl cysteine 600 mg / 12 hr
Intervention Type
DRUG
Dexamethasone
dexamethasone I.V 8 mg / day
Intervention Type
DRUG
Antibacterial therapies
Antibacterial drugs in their approved doses
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* inability to give informed consent by patients or their relative,
* history of hypersensitivity to milk products,
* history of lactoferrin use in the past 6 months,
* patients with lactose intolerance,
* patients with no enteral access to administer LF either orally or by Ryle tube,
* patients who are expected to die within 48 hours, and
* patients with poor oral absorption as in case of shock and resected bowel.
* history of hypersensitivity to milk products,
* history of lactoferrin use in the past 6 months,
* patients with lactose intolerance,
* patients with no enteral access to administer LF either orally or by Ryle tube,
* patients who are expected to die within 48 hours, and
* patients with poor oral absorption as in case of shock and resected bowel.
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed H Hassan, PharmD
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed H Hassan, Pharmacist
Role: PRINCIPAL_INVESTIGATOR
Mansoura University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mansoura University hospital
Al Mansurah, El-dakhlia, Egypt
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Egypt
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Artym J, Kocieba M, Zaczynska E, Adamik B, Kubler A, Zimecki M, Kruzel M. Immunomodulatory properties of human recombinant lactoferrin in mice: Implications for therapeutic use in humans. Adv Clin Exp Med. 2018 Mar;27(3):391-399. doi: 10.17219/acem/68440.
Reference Type
BACKGROUND
Hegazy, S.K., Hassan, A.H. The effect of combination treatment with casirivimab and imdevimab versus standard antiviral therapy on clinical outcomes in hospitalized COVID-19 patients. Discov Med 1, 71 (2024). https://doi.org/10.1007/s44337-024-00045-3
Reference Type
BACKGROUND
Baker HM, Baker EN. A structural perspective on lactoferrin function. Biochem Cell Biol. 2012 Jun;90(3):320-8. doi: 10.1139/o11-071. Epub 2012 Jan 31.
Reference Type
BACKGROUND
Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol. 2008;606:163-94. doi: 10.1007/978-0-387-74087-4_6.
Reference Type
BACKGROUND
Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, Garcia-Montoya IA, Salazar-Martinez J, Rascon-Cruz Q. Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin. 2014 May;35(5):557-66. doi: 10.1038/aps.2013.200.
Reference Type
BACKGROUND
Bukowska-Osko I, Popiel M, Kowalczyk P. The Immunological Role of the Placenta in SARS-CoV-2 Infection-Viral Transmission, Immune Regulation, and Lactoferrin Activity. Int J Mol Sci. 2021 May 28;22(11):5799. doi: 10.3390/ijms22115799.
Reference Type
BACKGROUND
Kowalczyk P, Kaczynska K, Kleczkowska P, Bukowska-Osko I, Kramkowski K, Sulejczak D. The Lactoferrin Phenomenon-A Miracle Molecule. Molecules. 2022 May 4;27(9):2941. doi: 10.3390/molecules27092941.
Reference Type
BACKGROUND
Poljsak B, Suput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013;2013:956792. doi: 10.1155/2013/956792. Epub 2013 Apr 29.
Reference Type
BACKGROUND
Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Osko I, Kucia M, Popiel M, Wietrak E, Kramkowski K, Wrzosek K, Kaczynska K. Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int J Mol Sci. 2021 Dec 13;22(24):13384. doi: 10.3390/ijms222413384.
Reference Type
BACKGROUND
Parekattil S.J., Esteves S.C., Agarwal A. Male Infertility. Springer; Berlin/Heidelberg, Germany: 2020. Harmful Effects of Antioxidant Therapy
Reference Type
BACKGROUND
Abdelhamid M, Jung CG, Zhou C, Abdullah M, Nakano M, Wakabayashi H, Abe F, Michikawa M. Dietary Lactoferrin Supplementation Prevents Memory Impairment and Reduces Amyloid-beta Generation in J20 Mice. J Alzheimers Dis. 2020;74(1):245-259. doi: 10.3233/JAD-191181.
Reference Type
BACKGROUND
Shi P, Fan F, Chen H, Xu Z, Cheng S, Lu W, Du M. A bovine lactoferrin-derived peptide induced osteogenesis via regulation of osteoblast proliferation and differentiation. J Dairy Sci. 2020 May;103(5):3950-3960. doi: 10.3168/jds.2019-17425. Epub 2020 Mar 18.
Reference Type
BACKGROUND
Moreno-Navarrete JM, Ortega FJ, Bassols J, Ricart W, Fernandez-Real JM. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin Endocrinol Metab. 2009 Oct;94(10):4036-44. doi: 10.1210/jc.2009-0215. Epub 2009 Jul 7.
Reference Type
BACKGROUND
Kaczmarek N, Jamka M, Walkowiak J. [An association of selected polymorphisms of the lactoferrin gene and genes for lactoferrin receptors in the prevalence of metabolic disorders in obese subjects]. Pol Merkur Lekarski. 2020 Apr 22;48(284):120-123. Polish.
Reference Type
BACKGROUND
Ikeda Y, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Yoshida S, Aihara K, Tsuchiya K, Tamaki T. Bovine milk-derived lactoferrin exerts proangiogenic effects in an Src-Akt-eNOS-dependent manner in response to ischemia. J Cardiovasc Pharmacol. 2013 May;61(5):423-9. doi: 10.1097/FJC.0b013e318287d526.
Reference Type
BACKGROUND
Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. Biochimie. 2009 Jan;91(1):19-29. doi: 10.1016/j.biochi.2008.05.015. Epub 2008 Jun 5.
Reference Type
BACKGROUND
Artym J, Zimecki M. Milk-derived proteins and peptides in clinical trials. Postepy Hig Med Dosw (Online). 2013 Aug 6;67:800-16. doi: 10.5604/17322693.1061635.
Reference Type
BACKGROUND
Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C. Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr. 2012 Oct 31;38:63. doi: 10.1186/1824-7288-38-63.
Reference Type
BACKGROUND
Wu J, Chen J, Wu W, Shi J, Zhong Y, van Tol EA, Tang Q, Cai W. Enteral supplementation of bovine lactoferrin improves gut barrier function in rats after massive bowel resection. Br J Nutr. 2014 Aug 28;112(4):486-92. doi: 10.1017/S000711451400107X. Epub 2014 May 15.
Reference Type
BACKGROUND
Sherman MP, Sherman J, Arcinue R, Niklas V. Randomized Control Trial of Human Recombinant Lactoferrin: A Substudy Reveals Effects on the Fecal Microbiome of Very Low Birth Weight Infants. J Pediatr. 2016 Jun;173 Suppl:S37-42. doi: 10.1016/j.jpeds.2016.02.074.
Reference Type
BACKGROUND
Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, Valenti P. Antiviral properties of lactoferrin--a natural immunity molecule. Molecules. 2011 Aug 16;16(8):6992-7018. doi: 10.3390/molecules16086992.
Reference Type
BACKGROUND
Miotto M, Di Rienzo L, Bo L, Boffi A, Ruocco G, Milanetti E. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin. Front Mol Biosci. 2021 Feb 15;8:607443. doi: 10.3389/fmolb.2021.607443. eCollection 2021.
Reference Type
BACKGROUND
Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, Bollani L, Rinaldi M, Gallo E, Quercia M, Maule M, Mostert M, Decembrino L, Magaldi R, Mosca F, Vagnarelli F, Memo L, Betta PM, Stronati M, Farina D; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections-the Italian Society of Neonatology. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. 2012 Jan;129(1):116-23. doi: 10.1542/peds.2011-0279. Epub 2011 Dec 19.
Reference Type
BACKGROUND
León-Sicairos N., Ordaz-Pichardo C., Carrero J.C., de la Garza M. Natural Remedies in the Fight Against Parasites. Intechopen; London, UK: 2017. Lactoferrin in the Battle against Intestinal Parasites: A Review.
Reference Type
BACKGROUND
Yamauchi K, Wakabayashi H, Shin K, Takase M. Bovine lactoferrin: benefits and mechanism of action against infections. Biochem Cell Biol. 2006 Jun;84(3):291-6. doi: 10.1139/o06-054.
Reference Type
BACKGROUND
Alexander DB, Iigo M, Abdelgied M, Ozeki K, Tanida S, Joh T, Takahashi S, Tsuda H. Bovine lactoferrin and Crohn's disease: a case study. Biochem Cell Biol. 2017 Feb;95(1):133-141. doi: 10.1139/bcb-2016-0107. Epub 2016 Nov 30.
Reference Type
BACKGROUND
He S, McEuen AR, Blewett SA, Li P, Buckley MG, Leufkens P, Walls AF. The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G. Biochem Pharmacol. 2003 Mar 15;65(6):1007-15. doi: 10.1016/s0006-2952(02)01651-9.
Reference Type
BACKGROUND
Wakabayashi H, Yamauchi K, Abe F. Quality control of commercial bovine lactoferrin. Biometals. 2018 Jun;31(3):313-319. doi: 10.1007/s10534-018-0098-2. Epub 2018 Apr 4.
Reference Type
BACKGROUND
Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C. Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. Acta Obstet Gynecol Scand. 2009;88(9):1031-5. doi: 10.1080/00016340903117994.
Reference Type
BACKGROUND
Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 2020 Sep;56(3):106118. doi: 10.1016/j.ijantimicag.2020.106118. Epub 2020 Jul 30.
Reference Type
BACKGROUND
Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800. doi: 10.1097/00003246-199811000-00016.
Reference Type
BACKGROUND
Eltahan NH, Elsawy NH, Abdelaaty KM, Elhamaky AS, Hassan AH, Emara MM. Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial. Respir Res. 2024 Feb 22;25(1):97. doi: 10.1186/s12931-024-02732-2.
Reference Type
BACKGROUND
Hegazy SK, Tharwat S, Hassan AH. Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients. J Clin Virol Plus. 2023 Jun;3(2):100151. doi: 10.1016/j.jcvp.2023.100151. Epub 2023 May 10.
Reference Type
BACKGROUND
Hegazy SK, Tharwat S, Hassan AH. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients. Open Med (Wars). 2023 Aug 9;18(1):20230768. doi: 10.1515/med-2023-0768. eCollection 2023.
Reference Type
BACKGROUND
Hegazy SK, Tharwat S, Hassan AH. Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients. World J Clin Cases. 2023 Sep 16;11(26):6105-6121. doi: 10.12998/wjcc.v11.i26.6105.
Reference Type
BACKGROUND
Hegazy SK, Hassan AH. Comparing the Efficacy of Remdesivir, Favipiravir, and Casirivimab and Imdevimab on Duration of Hospitalization and ICU Stay of Hospitalized COVID-19 Patients. Life Science Research Communications; 2024; 1(1),21-30. Available at: https://doi.org/10.5530/lsrc.1.1.7
Reference Type
BACKGROUND
Hassan AH, Hegazy SK, Radwan ST. Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against Corona virus 2 infection in hospitalized COVID-19 patients. medRxiv. 2022. (preprint). Available from: doi: 10.1101/2022.08.20.22279020
Reference Type
BACKGROUND
Hassan AH, Hegazy SK, Radwan ST. Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against Corona virus 2 infection in hospitalized COVID-19 patients. Research Square; 2023. Available from: doi: 10.21203/rs.3.rs-1991618/v2.
Reference Type
BACKGROUND
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual Participant Data Set
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35039/9/23
Identifier Type: OTHER
Identifier Source: secondary_id
MD.23.09.800
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effects of 10 Days of Extreme Endurance on Performance
NCT03337737
COMPLETED
NA
Accelerating Recovery After ICU Admission: Post-discharge Supplementation With Pasteurized Akkermansia Muciniphila.
NCT07295353
NOT_YET_RECRUITING
NA
Evaluation of the Ketogenic Potential of Different Diet Supplements
NCT02693106
COMPLETED
NA
Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease
NCT04623619
UNKNOWN
NA
Nutritional Supplement for Patients With Severe Infection
NCT05602324
UNKNOWN
NA
Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients
NCT04792021
COMPLETED
PHASE3
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
NCT03318731
COMPLETED
NA
Oral Nutritional Supplements in Treatment of Elderly Mild-to-Moderate COVID-19
NCT05629975
UNKNOWN
NA
Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors
NCT03444558
COMPLETED
NA
Effects of Lactobacillus Paracasei PS23 on Anti-fatigue
NCT05346432
COMPLETED
NA
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19
NCT04323228
UNKNOWN
PHASE2/PHASE3
The Effects of L-arginine Supplementation on Anaerobic Exercise Performance
NCT06475391
RECRUITING
NA
Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers
NCT01056094
UNKNOWN
PHASE1/PHASE2
Effects of Decohexaenoic Acid Supplementation on Markers of Inflammatory Muscle Damage
NCT04125199
COMPLETED
NA
Effects of a Multi-Ingredient Pre-Workout Supplement on Energy Expenditure During Running
NCT04352998
COMPLETED
NA
The Effect of Colostrum Bovinum Supplementation in Endurance Athletes
NCT06390670
COMPLETED
PHASE2/PHASE3
Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance
NCT04712578
COMPLETED
NA
The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular Markers
NCT05297097
UNKNOWN
PHASE2
Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors
NCT04592354
UNKNOWN
NA
Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
NCT06937190
RECRUITING
NA
The Effects of Ketone Supplements With Carbohydrates on Cycling Performance Above Lactate Threshold
NCT07224282
NOT_YET_RECRUITING
EARLY_PHASE1
A Replicate Crossover Trial on Nutritional Supplementation in Association Football (Soccer)
NCT07190989
COMPLETED
NA
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus
NCT05446961
COMPLETED
PHASE2
Effects of Maca Supplementation on Badminton-specific Exercise Performance
NCT07082985
COMPLETED
NA
A Novel Iron Supplement for Athletes: Phase I
NCT06285851
COMPLETED
NA